Literature DB >> 26310715

Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.

Lidia Giraudo1,2, Loretta Gammaitoni2, Michela Cangemi2, Ramona Rotolo2, Massimo Aglietta1,3, Dario Sangiolo1,2.   

Abstract

Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes endowed with potent MHC-independent antitumor activity. CIK cells are emerging as promising therapeutic approach in the field of cancer adoptive immunotherapy, with biologic features favoring their transferability into clinical applications. Aim of this review is to present the biologic characteristic of CIK cells, discussing the main preclinical findings and initial clinical applications in the field of solid tumors.

Entities:  

Keywords:  adoptive immunotherapy; cytokine-induced killer cells; solid tumors

Mesh：

Substances：

Year:  2015        PMID： 26310715     DOI： 10.2217/imt.15.61

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  16 in total

1.  HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

Authors:  Zijun Zhen; Kaibin Yang; Litong Ye; Zhiyao You; Rirong Chen; Ying Liu; Youjian He
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

2.  Targeting sarcoma tumor-initiating cells through differentiation therapy.

Authors:  Dan Han; Veronica Rodriguez-Bravo; Elizabeth Charytonowicz; Elizabeth Demicco; Josep Domingo-Domenech; Robert G Maki; Carlos Cordon-Cardo
Journal:  Stem Cell Res       Date:  2017-04-13       Impact factor: 2.020

3.  CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.

Authors:  Valeria Leuci; Chiara Donini; Giovanni Grignani; Ramona Rotolo; Giulia Mesiano; Erika Fiorino; Loretta Gammaitoni; Lorenzo D'Ambrosio; Alessandra Merlini; Elisa Landoni; Enzo Medico; Sonia Capellero; Lidia Giraudo; Giulia Cattaneo; Ilenia Iaia; Ymera Pignochino; Marco Basiricò; Elisa Vigna; Alberto Pisacane; Franca Fagioli; Soldano Ferrone; Massimo Aglietta; Gianpietro Dotti; Dario Sangiolo
Journal:  Clin Cancer Res       Date:  2020-09-08       Impact factor: 12.531

4.  Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma.

Authors:  Dai Liu; Kevin F Staveley-O'Carroll; Guangfu Li
Journal:  J Clin Cell Immunol       Date:  2015-12-10

5.  Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.

Authors:  Alberto L Horenstein; Antonella Chillemi; Roberta Zini; Valeria Quarona; Nicoletta Bianchi; Rossella Manfredini; Roberto Gambari; Fabio Malavasi; Davide Ferrari
Journal:  Front Pharmacol       Date:  2018-04-20       Impact factor: 5.810

6.  Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models.

Authors:  Ilenia Iaia; Loretta Gammaitoni; Giulia Cattaneo; Lidia Giraudo; Chiara Donini; Erika Fiorino; Luca Primo; Fabrizio Carnevale-Schianca; Massimo Aglietta; Alberto Puliafito; Dario Sangiolo
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

7.  CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Authors:  V Leuci; G M Casucci; G Grignani; R Rotolo; U Rossotti; E Vigna; L Gammaitoni; G Mesiano; E Fiorino; C Donini; A Pisacane; L D Ambrosio; Y Pignochino; M Aglietta; A Bondanza; D Sangiolo
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

8.  Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.

Authors:  Michael Merker; Verena Pfirrmann; Sarah Oelsner; Simone Fulda; Thomas Klingebiel; Winfried S Wels; Peter Bader; Eva Rettinger
Journal:  Oncotarget       Date:  2017-08-02

Review 9.  Cancer Stem Cells in Soft-Tissue Sarcomas.

Authors:  Paula Martínez-Delgado; Serena Lacerenza; Antonia Obrador-Hevia; Maria Lopez-Alvarez; José L Mondaza-Hernandez; Elena Blanco-Alcaina; Paloma Sanchez-Bustos; Nadia Hindi; David S Moura; Javier Martin-Broto
Journal:  Cells       Date:  2020-06-10       Impact factor: 6.600

10.  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.

Authors:  Anna Dalla Pietà; Elisa Cappuzzello; Roberta Sommaggio; Antonio Rosato; Pierangela Palmerini; Annavera Ventura; Andrea Visentin; Giuseppe Astori; Katia Chieregato; Valentina Mozzo; Omar Perbellini; Maria Chiara Tisi; Livio Trentin; Carlo Visco; Marco Ruggeri
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.